NET PROFIT (x1000 EUR)
EMPLOYEES
Ascelia Pharma AB
Closing information (x1000 EUR)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover |
0
![]() |
0
![]() |
0 |
Financial expenses |
356
|
197
|
1,805 |
Earnings before taxes |
-11,965
|
-12,665
|
-9,937 |
EBITDA |
-13,116
|
-13,388 | |
Total assets |
19,641
|
32,609
|
25,442 |
Current assets |
14,456
|
26,852
|
19,559 |
Current liabilities |
3,371
|
2,455
|
1,829 |
Equity capital |
16,252
|
30,100
|
23,517 |
- share capital |
3,134
|
3,381
|
2,340 |
Employees (average) |
22
|
20
|
11 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency |
82.7%
|
92.3%
|
92.4% |
Turnover per employee |
0
![]() |
0
![]() |
0 |
Profit as a percentage of turnover | |||
Return on assets (ROA) |
-59.1%
|
-38.2%
|
-32.0% |
Current ratio |
428.8%
|
1093.8%
|
1069.4% |
Return on equity (ROE) |
-73.6%
|
-42.1%
|
-42.3% |
Change turnover |
0
![]() |
0
![]() |
0 |
Change turnover % | |||
Chg. No. of employees |
2
|
9
|
4 |
Chg. No. of employees % |
10%
|
82%
|
57% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.